|
|
|
ALNY Description — Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals is a global biopharmaceutical company developing therapeutics based on ribonucleic acid interference (RNAi). Co. has four RNAi-based medicines, ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran) and Leqvio® (inclisiran). ONPATTRO is approved for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. GIVLAARI is approved for the treatment of adults with acute hepatic porphyria. Co. has approval for OXLUMO for the treatment of primary hyperoxaluria type 1 in all age groups. Leqvio (inclisiran) is being developed and commercialized for the treatment of adults with hypercholesterolemia or mixed dyslipidemia.
Company Name: |
Alnylam Pharmaceuticals Inc |
Website: |
www.alnylam.com |
Sector: |
Drugs & Pharmaceuticals |
Number of ETFs Holding ALNY: |
57 |
Total Market Value Held by ETFs: |
$2,156,643,187.59 |
Total Market Capitalization: |
$19,437,000,000 |
% of Market Cap. Held by ETFs: |
11.10% |
|
ETF |
ALNY Weight |
ALNY Amount |
VTI |
0.04% |
$599,451,226 |
VO |
0.24% |
$393,957,813 |
VXF |
0.28% |
$283,886,605 |
VUG |
0.08% |
$182,580,131 |
VOT |
0.56% |
$135,225,592 |
XBI |
1.09% |
$73,165,820 |
IWP |
0.47% |
$66,769,303 |
VHT |
0.30% |
$60,850,572 |
IWR |
0.17% |
$57,440,476 |
IWF |
0.06% |
$51,598,680 |
List of all 57 ETFs holding ALNY
» |
|
|
|
|
Buy (3.16 out of 4)
37th percentile
|
PARTNER NEWS:Fri, May 3, 10:29 AM, Zacks
Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y Alnylam (ALNY) reports better-than-expected first-quarter 2024 results as both earnings and revenues beat estimates, primarily driven by strong Amvuttra sales.
Wed, May 1, 8:15 AM, Zacks
Annexon (ANNX) to Report Q1 Earnings: What's in the Cards? Annexon (ANNX) is expected to provide updates from the phase III study evaluating its lead candidate, ANX005, for the treatment of GBS in the first-quarter earnings release.
|
|